Is GNLX or KYTX more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Kyverna Therapeutics N/A -81.92% -63.74%

Does the media favor GNLX or KYTX?

In the previous week, Genelux had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Genelux and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Genelux's score of 0.54 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ELYM or GNLX?

Genelux has a consensus price target of $18.00, indicating a potential upside of 622.89%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ELYM or GNLX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Genelux N/A -205.85% -138.79%

Do analysts rate PRTC or GNLX?

Genelux has a consensus price target of $18.00, suggesting a potential upside of 622.89%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, PRTC or GNLX?

Genelux has lower revenue, but higher earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Genelux $10K 11,264.76 -$32.15M -$0.86 N/A

Is PRTC or GNLX more profitable?

PureTech Health's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Genelux N/A -205.85% -138.79%

Does the media refer more to ARCT or GNLX?

In the previous week, Genelux had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for Genelux and 3 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.07 beat Genelux's score of 0.54 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is GNLX or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Benitec Biopharma N/A -34.82% -34.11%

Genelux (GNLX) Competitors

$2.49 +0.01 (+0.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.56 +0.07 (+2.65%)

As of 09/11/2026 07:30 PM Eastern

Compare

GNLX vs. KYTX, ELYM, PRTC, ARCT, and BNTC

Should you buy Genelux stock or one of its competitors? Genelux's main competitors and comparable companies include Kyverna Therapeutics (KYTX), Eliem Therapeutics (ELYM), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), and Benitec Biopharma (BNTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genelux compare to Kyverna Therapeutics?

Genelux (NASDAQ:GNLX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Genelux has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Kyverna Therapeutics' return on equity of -81.92% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Genelux currently has a consensus target price of $18.00, suggesting a potential upside of 622.89%. Kyverna Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 313.22%. Given Genelux's higher probable upside, research analysts plainly believe Genelux is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

37.3% of Genelux shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Genelux had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Genelux and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Genelux's score of 0.54 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Genelux has higher revenue and earnings than Kyverna Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,264.76	-$32.15M	-$0.86	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Summary

Kyverna Therapeutics beats Genelux on 8 of the 14 factors compared between the two stocks.

How does Genelux compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, Genelux has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, Genelux had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Genelux and 0 mentions for Eliem Therapeutics. Genelux's average media sentiment score of 0.54 beat Eliem Therapeutics' score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Genelux	Positive

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genelux has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Genelux	$10K	11,264.76	-$32.15M	-$0.86	N/A

Eliem Therapeutics' return on equity of -47.03% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Genelux	N/A	-205.85%	-138.79%

Genelux has a consensus price target of $18.00, indicating a potential upside of 622.89%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genelux beats Eliem Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Genelux compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

PureTech Health's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Genelux	N/A	-205.85%	-138.79%

Genelux has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Genelux	$10K	11,264.76	-$32.15M	-$0.86	N/A

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Genelux has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, Genelux had 4 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Genelux and 0 mentions for PureTech Health. Genelux's average media sentiment score of 0.54 beat PureTech Health's score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Genelux	Positive

Genelux has a consensus price target of $18.00, suggesting a potential upside of 622.89%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genelux beats PureTech Health on 9 of the 13 factors compared between the two stocks.

How does Genelux compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Arcturus Therapeutics has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market. Comparatively, Genelux has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Arcturus Therapeutics currently has a consensus target price of $23.00, indicating a potential upside of 56.14%. Genelux has a consensus target price of $18.00, indicating a potential upside of 622.89%. Given Genelux's higher probable upside, analysts clearly believe Genelux is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Genelux had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for Genelux and 3 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.07 beat Genelux's score of 0.54 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Genelux has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$18.72M	22.36	-$65.78M	-$3.31	N/A
Genelux	$10K	11,264.76	-$32.15M	-$0.86	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genelux has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Genelux	N/A	-205.85%	-138.79%

Summary

Arcturus Therapeutics beats Genelux on 10 of the 17 factors compared between the two stocks.

How does Genelux compare to Benitec Biopharma?

Genelux (NASDAQ:GNLX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 622.89%. Benitec Biopharma has a consensus price target of $24.80, indicating a potential upside of 103.45%. Given Genelux's higher possible upside, research analysts plainly believe Genelux is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma's return on equity of -34.82% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Benitec Biopharma	N/A	-34.82%	-34.11%

Genelux has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,264.76	-$32.15M	-$0.86	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Genelux has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Genelux had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Genelux and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat Genelux's score of 0.54 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Positive
Benitec Biopharma	Very Positive

37.3% of Genelux shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Genelux beats Benitec Biopharma on 8 of the 14 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.66M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.90	8.38	214.57	20.80
Price / Sales	11,264.76	1,378.81	633.76	90.54
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	8.30	15.12	10.33	6.20
Net Income	-$32.15M	-$22.86M	$3.50B	$358.50M
7 Day Performance	2.05%	-4.34%	-3.32%	-2.35%
1 Month Performance	-7.78%	-0.02%	-0.41%	-2.77%
1 Year Performance	-36.96%	40.64%	19.21%	7.63%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	2.0805 of 5 stars	$2.49 +0.4%	$18.00 +622.9%	-31.8%	$112.66M	$10K	N/A	10	Gap Up
KYTX Kyverna Therapeutics	2.0839 of 5 stars	$7.30 -0.7%	$30.00 +311.2%	+74.9%	$451.49M	N/A	N/A	96	Positive News
ELYM Eliem Therapeutics	N/A	$14.95 -0.7%	N/A	+528.2%	$444.79M	N/A	N/A	9	High Trading Volume
PRTC PureTech Health	N/A	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
ARCT Arcturus Therapeutics	3.0134 of 5 stars	$14.91 +6.7%	$23.00 +54.3%	-18.3%	$423.29M	$82.03M	N/A	180	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. KYTX, ELYM, PRTC, ARCT, and BNTC

How does Genelux compare to Kyverna Therapeutics?

Summary

How does Genelux compare to Eliem Therapeutics?

Summary

How does Genelux compare to PureTech Health?

Summary

How does Genelux compare to Arcturus Therapeutics?

Summary

How does Genelux compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. KYTX, ELYM, PRTC, ARCT, and BNTC

How does Genelux compare to Kyverna Therapeutics?

Which has more volatility and risk, GNLX or KYTX?

Is GNLX or KYTX more profitable?

Do analysts rate GNLX or KYTX?

Do insiders and institutionals hold more shares of GNLX or KYTX?

Does the media favor GNLX or KYTX?

Which has stronger earnings and valuation, GNLX or KYTX?

Summary

How does Genelux compare to Eliem Therapeutics?

Which has more risk and volatility, ELYM or GNLX?

Does the media refer more to ELYM or GNLX?

Do institutionals & insiders believe in ELYM or GNLX?

Which has higher earnings and valuation, ELYM or GNLX?

Is ELYM or GNLX more profitable?

Do analysts prefer ELYM or GNLX?

Summary

How does Genelux compare to PureTech Health?

Is PRTC or GNLX more profitable?

Which has higher valuation & earnings, PRTC or GNLX?

Do institutionals and insiders hold more shares of PRTC or GNLX?

Which has more volatility & risk, PRTC or GNLX?

Does the media favor PRTC or GNLX?

Do analysts rate PRTC or GNLX?

Summary

How does Genelux compare to Arcturus Therapeutics?

Which has more risk & volatility, ARCT or GNLX?

Do analysts prefer ARCT or GNLX?

Does the media refer more to ARCT or GNLX?

Which has stronger earnings & valuation, ARCT or GNLX?

Do insiders and institutionals believe in ARCT or GNLX?

Is ARCT or GNLX more profitable?

Summary

How does Genelux compare to Benitec Biopharma?

Do analysts prefer GNLX or BNTC?

Is GNLX or BNTC more profitable?

Which has better valuation & earnings, GNLX or BNTC?

Which has more risk and volatility, GNLX or BNTC?

Does the media refer more to GNLX or BNTC?

Do insiders & institutionals believe in GNLX or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools